full-width
false
full-width
Are you ready to take TACE to the next level?
TACE is standard of care in the BCLC guidelines for HCC, and we recognise that there is still scope for improvement, for example complete response rates, duration of response, leading to the need for retreatment.
As Terumo we are proud that we have generated in recent years a large set of clinical data leading to a new concept of advanced TACE. Several recent clinical publications using the Terumo portfolio have shown new evidence to further improve TACE.
This evidence could further strengthen the case for TACE at the oncological tumour board.
neutrals-100
Clinical Data
2
neutrals-100
The latest clinical evidence with the Terumo portfolio in DEM-TACE and Occlusafe-TACE brings new perspectives on the future of TACE treatment:
- A pooled analysis from over 580 patients with unrestable HCC treated with DEM-TACE will support your practice of DEM-TACE in tumour board discussions. This data is published in CVIR (2023) and was also presented in major oncological congresses, including ESMO GI 2020 and ASCO GI 2021.
- Long term outcomes of Occlusafe B-TACE demonstrated a high mean overall survival of over 4 years with 50.0 months [namely 51.4 months for patients BCLC A and 42.1 for patients BCLC B1] vs an expected 2.5 years Overall survival in BCLC B patients4
neutrals-100
Learn more about Advanced TACE clinical data
Learn more about Advanced TACE clinical data
tisPrimary
pd-y-64
Taking TACE to the next level
Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy.
Improving complete response rates and maintaining this response lead to an increase in overall survival1:
- DEM-TACE treatments reach high complete response rates1
- 60.1% Complete response rate leading to over 4 years overall survival (50.8month) (n=580 patients)1
- Even when multiple treatments are required for larger, complex tumours2
- 20% of patients achieved complete response after 3rd or 4th TACE procedures (n=97)2
grid-texts-50
text-vertical-top
image-media-type
default-aspect-ratio
media-left
false
Long term clinical outcomes demonstrate that Occlusafe B-TACE allows to get similar clinical outcomes as with LifePearlTM microspheres1 DEM-TACE but in HCC lesions > 3 cm3
OcclusafeTM-TACE demonstrated to be efficient for the oncological management of HCC with the following results3:
- Complete response in 58.9% of patients at 6 months3
- Median local recurrence-free survival of 31.0 months3
- Over 4 years mean Overall Survival with 50 months [namely 51.4 months for patients BCLC A and 42.1 for patients BCLC B1] vs an expected 2.5 years Overall survival in BCLC B patients4
grid-texts-50
text-vertical-top
image-media-type
default-aspect-ratio
media-right
false
Breaking new data with Advanced TACE
Presentations from ECIO 2021
brightcove
6363678750112
DEM TACE
6363678749112
Occlusafe TACE
What the evidence says
3
neutrals-100
Discover our clinical evidence and case studies concerning this topic.
neutrals-100
terumo-product-tag:occlusafe™,terumo-product-tag:lifepearl™
View all clinical evidences
View all clinical evidences
link
References
Veloso Gomes et al Cardiovasc Intervent Radiol 2023 (Pooled analysis)
link
de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)
link
de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)
Lucatelli et al: Cardiovasc Intervent Radiol https://doi.org/10.1007/s00270-024-03779-w
link
Lucatelli et al: Cardiovasc Intervent Radiol https://doi.org/10.1007/s00270-024-03779-w
Reig et al - BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update – journal of Hepatology VOLUME 76, ISSUE 3, P681-693, MARCH 2022
link
Reig et al - BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update – journal of Hepatology VOLUME 76, ISSUE 3, P681-693, MARCH 2022
Featured products
2
neutrals-100
default-carousel
default-carousel
LifePearl™
Drug Elutable Microspheres
default-carousel
Occlusafe™
Temporary Occlusion Balloon Microcatheter
Occlusafe™ is not available for sale in all countries. Please contact your Terumo local sales representative for more information. Occlusafe™ has not been approved by the FDA and is therefore not available for sale in the U.S.A. Occlusafe™ is intended for use in the peripheral vasculature where temporary occlusion is desired. It provides temporary vascular occlusion, which is useful in selectively stopping or controlling blood flow. Occlusafe™ is also intended for use in the peripheral vasculature for the infusion of contrast media, drugs and embolic materials.
Progreat™ Micro Catheter System is indicated for therapeutic embolization and angiography in peripheral vessels. Progreat™ Micro Catheter System is not available for sale in all countries. Please contact your Terumo local sales representative for more information.
Progreat λ™ Micro Catheter System is intended for use in the peripheral vasculature for the infusion of contrast media, drugs and embolic materials in intravascular therapy. Progreat λ™ Micro Catheter System is not available for sale in all countries. Please contact your Terumo local sales representative for more information.
LifePearl™ microspheres are indicated for embolization of blood vessels supplying primary hypervascular tumours or metastases in the liver. Note: LifePearl™ microspheres can be loaded and release chemotherapeutic agents such as Doxorubicin, Epirubicin, Idarubicin and Irinotecan. When used for drug loading, drug loading should be done under a physician’s direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. LifePearl™ microspheres can be drug loaded prior to embolization and release in a local and controlled manner the chemotherapeutic agents to the tumours after the embolization procedure. Lifepearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. The use of the LifePearl™ microspheres device is not cleared or approved in the U.S.A. by the Food and Drug Administration. Lifepearl™ microspheres are not approved in Canada. Please contact your Terumo local sales representative for more information.
BioPearl™microspheres are indicated for embolization of blood vessels supplying primary-hypervascular tumours or metastases in the liver. Note: BioPearl™ microspheres can be loaded with chemotherapeutic drugs. When used for drug loading, drug loading should be done under a physician’s direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. BioPearl™ microspheres are compatible with Doxorubicin, Epirubicin, and Idarubicin. BioPearl™ microspheres can be drug loaded prior to embolization and then, as a secondary action, elute a local, controlled, and sustained dose to the targeted tumour sites after embolization. BioPearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. BioPearl™ microspheres are not approved in the USA by the Food and Drug Administration. BioPearl™ microspheres are not approved in Canada. Please contact your Terumo local sales representative for more information.
LifePearl™ and BioPearl™ microspheres are manufactured by MicroVention Europe and exclusively distributed by Terumo Europe NV in EMEA region. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. Refer to Instructions for Use for Contraindications, Warnings and Precautions. ©2024 MicroVention. CE0297 – Manufacturer MicroVention Europe SARL – 30 bis, rue du Vieil Abreuvoir 78100 Saint-Germain-en-Laye FRANCE – Tel: +33(0)1 39 21 77 64 – Fax: +33(0)1 39 21 16
Progreat™ Micro Catheter System is indicated for therapeutic embolization and angiography in peripheral vessels. Progreat™ Micro Catheter System is not available for sale in all countries. Please contact your Terumo local sales representative for more information.
Progreat λ™ Micro Catheter System is intended for use in the peripheral vasculature for the infusion of contrast media, drugs and embolic materials in intravascular therapy. Progreat λ™ Micro Catheter System is not available for sale in all countries. Please contact your Terumo local sales representative for more information.
LifePearl™ microspheres are indicated for embolization of blood vessels supplying primary hypervascular tumours or metastases in the liver. Note: LifePearl™ microspheres can be loaded and release chemotherapeutic agents such as Doxorubicin, Epirubicin, Idarubicin and Irinotecan. When used for drug loading, drug loading should be done under a physician’s direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. LifePearl™ microspheres can be drug loaded prior to embolization and release in a local and controlled manner the chemotherapeutic agents to the tumours after the embolization procedure. Lifepearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. The use of the LifePearl™ microspheres device is not cleared or approved in the U.S.A. by the Food and Drug Administration. Lifepearl™ microspheres are not approved in Canada. Please contact your Terumo local sales representative for more information.
BioPearl™microspheres are indicated for embolization of blood vessels supplying primary-hypervascular tumours or metastases in the liver. Note: BioPearl™ microspheres can be loaded with chemotherapeutic drugs. When used for drug loading, drug loading should be done under a physician’s direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. BioPearl™ microspheres are compatible with Doxorubicin, Epirubicin, and Idarubicin. BioPearl™ microspheres can be drug loaded prior to embolization and then, as a secondary action, elute a local, controlled, and sustained dose to the targeted tumour sites after embolization. BioPearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. BioPearl™ microspheres are not approved in the USA by the Food and Drug Administration. BioPearl™ microspheres are not approved in Canada. Please contact your Terumo local sales representative for more information.
LifePearl™ and BioPearl™ microspheres are manufactured by MicroVention Europe and exclusively distributed by Terumo Europe NV in EMEA region. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. Refer to Instructions for Use for Contraindications, Warnings and Precautions. ©2024 MicroVention. CE0297 – Manufacturer MicroVention Europe SARL – 30 bis, rue du Vieil Abreuvoir 78100 Saint-Germain-en-Laye FRANCE – Tel: +33(0)1 39 21 77 64 – Fax: +33(0)1 39 21 16
neutrals-100